Terms: = Breast cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Treatment
23 results:
1. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP; Bagegni NA; Batist G; Brufsky A; Cristofanilli MA; Damodaran S; Daniel BR; Fleming GF; Gradishar WJ; Graff SL; Grosse Perdekamp MT; Hamilton E; Lavasani S; Moreno-Aspitia A; O'Connor T; Pluard TJ; Rugo HS; Sammons SL; Schwartzberg LS; Stover DG; Vidal GA; Wang G; Warner E; Yerushalmi R; Plourde PV; Portman DJ; Gal-Yam EN
Ann Oncol; 2023 Dec; 34(12):1141-1151. PubMed ID: 38072514
[TBL] [Abstract] [Full Text] [Related]
2. Carcinogenic roles of mafG-AS1 in human cancers.
Ahmadi M; Morshedzadeh F; Ghaderian SMH; Mousavi P; Habibipour L; Peymani M; Abbaszadegan MR; Ghafouri-Fard S
Clin Transl Oncol; 2024 Jan; 26(1):52-68. PubMed ID: 37351806
[TBL] [Abstract] [Full Text] [Related]
3. The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative breast cancer: A Systemic Review and Meta-Analysis.
Ergun Y; Akagunduz B; Karacin C; Turker S; Ucar G
Clin Breast Cancer; 2023 Aug; 23(6):567-575. PubMed ID: 37336652
[TBL] [Abstract] [Full Text] [Related]
4. Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R
J Bone Miner Metab; 2023 May; 41(3):290-300. PubMed ID: 37162605
[TBL] [Abstract] [Full Text] [Related]
5. Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments.
Yang Y; Jiang Y; Xie B; Shi S; Pi F; Chen M; Sang C; Xu L; Chen T
Biomater Sci; 2023 Feb; 11(4):1517-1529. PubMed ID: 36606484
[TBL] [Abstract] [Full Text] [Related]
6. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
8.
Paterson AHG; Lucas PC; Anderson SJ; Mamounas EP; Brufsky A; Baez-Diaz L; King KM; Lad T; Robidoux A; Finnigan M; Sampayo M; Tercero JC; Mairet JJ; Wolff AC; Fehrenbacher L; Wolmark N; Gomis RR
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377934
[TBL] [Abstract] [Full Text] [Related]
9. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for treatment Monitoring in Metastatic breast cancer.
Gerratana L; Davis AA; Zhang Q; Basile D; Rossi G; Strickland K; Franzoni A; Allegri L; Mu Z; Zhang Y; Flaum LE; Damante G; Gradishar WJ; Platanias LC; Behdad A; Yang H; Puglisi F; Cristofanilli M
JCO Precis Oncol; 2021 Jun; 5():943-952. PubMed ID: 34136741
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of Arylsulfatase D (ARSD) and long noncoding RNA ARSD-AS1 gene expression in breast cancer patients and their association with oncogenic transcription factors.
Bahramian S; T Shamsabadi F; Fazel A; Delshad E; Amini A; Memari F; Shafiee M
J BUON; 2020; 25(4):1805-1813. PubMed ID: 33099917
[TBL] [Abstract] [Full Text] [Related]
11. Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.
Toldi G; Batel P; Baráth S; Szerémy P; Apjok A; Filkor K; Szántó S; Szűcs G; Szamosi S; Häupl T; Grützkau A; Szekanecz Z
J Rheumatol; 2019 Jun; 46(6):572-578. PubMed ID: 30709954
[TBL] [Abstract] [Full Text] [Related]
12. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
13. Effect of maf amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Coleman R; Hall A; Albanell J; Hanby A; Bell R; Cameron D; Dodwell D; Marshall H; Jean-Mairet J; Tercero JC; Rojo F; Gregory W; Gomis RR
Lancet Oncol; 2017 Nov; 18(11):1543-1552. PubMed ID: 29037984
[TBL] [Abstract] [Full Text] [Related]
14. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in breast cancer Patients.
Makhoul I; Todorova VK; Siegel ER; Erickson SW; Dhakal I; Raj VR; Lee JY; Orloff MS; Griffin RJ; Henry-Tillman RS; Klimberg S; Hutchins LF; Kadlubar SA
PLoS One; 2017; 12(1):e0168550. PubMed ID: 28045923
[TBL] [Abstract] [Full Text] [Related]
15. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer.
Merriman JD; Aouizerat BE; Cataldo JK; Dunn L; Cooper BA; West C; Paul SM; Baggott CR; Dhruva A; Kober K; Langford DJ; Leutwyler H; Ritchie CS; Abrams G; Dodd M; Elboim C; Hamolsky D; Melisko M; Miaskowski C
Cytokine; 2014 Feb; 65(2):192-201. PubMed ID: 24315345
[TBL] [Abstract] [Full Text] [Related]
16. Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2).
Huan J; Wang L; Xing L; Qin X; Feng L; Pan X; Zhu L
Gene; 2014 Jan; 533(1):346-55. PubMed ID: 23978611
[TBL] [Abstract] [Full Text] [Related]
17. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract] [Full Text] [Related]
18. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (Gcmaf).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract] [Full Text] [Related]
19. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
Hernández-Vargas H; Rodríguez-Pinilla SM; Julián-Tendero M; Sánchez-Rovira P; Cuevas C; Antón A; Ríos MJ; Palacios J; Moreno-Bueno G
Breast Cancer Res Treat; 2007 Apr; 102(2):157-72. PubMed ID: 17039268
[TBL] [Abstract] [Full Text] [Related]
20. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment.
Roscoe JA; Morrow GR; Hickok JT; Bushunow P; Matteson S; Rakita D; Andrews PL
Support Care Cancer; 2002 May; 10(4):329-36. PubMed ID: 12029433
[TBL] [Abstract] [Full Text] [Related]
[Next]
